scholarly journals The Optimal Activity of Radioactive Iodine for Remnant Ablation in Low/Intermediate Risk Differentiated Thyroid Carcinoma: A Continuous Controversy and Meta-Analysis

Cureus ◽  
2021 ◽  
Author(s):  
Hyder Mirghani ◽  
Mohammed I Altidlawi ◽  
Ibrahim A Altedlawi Albalawi
Keyword(s):  
Thyroid Carcinoma ◽  
Radioactive Iodine ◽  
Meta Analysis ◽  
Differentiated Thyroid Carcinoma ◽  
Intermediate Risk ◽  
Remnant Ablation ◽  
Optimal Activity

scholarly journals Risk stratification of 282 differentiated thyroid cancers found incidentally in 1369 total thyroidectomies according to the 2015 ATA guidelines; implications for management and treatment

2018 ◽  
Vol 100 (5) ◽  
pp. 357-365 ◽  
Author(s):  
I Christakis ◽  
S Dimas ◽  
ID Kafetzis ◽  
N Roukounakis
Keyword(s):  
Thyroid Carcinoma ◽  
Preoperative Diagnosis ◽  
Radioactive Iodine ◽  
Risk Group ◽  
Differentiated Thyroid Carcinoma ◽  
Stage I ◽  
American Thyroid Association ◽  
Intermediate Risk ◽  
Incidental Group ◽  
Iodine Treatment

Introduction The purpose of this study was to evaluate the incidence of incidental differentiated thyroid carcinoma in thyroid operations for a benign preoperative diagnosis, to identify the risk factors involved and to risk stratify the cancer patients according to the 2015 American Thyroid Association (ATA) guidelines. Materials and methods The study was a retrospective review of all thyroidectomy operations performed in a single institution (January 2004 to January 2009). We excluded patients with a preoperative diagnosis of thyroid malignancy. Results Incidental differentiated thyroid carcinoma was diagnosed in 282/1369 patients (21%). The incidental group had a significantly higher number of males (19% vs 14%, P = 0.033) and a higher number of patients with histopathological evidence of thyroiditis (35% vs 25%, P = 0.004). There was a higher number of lymph nodes present in the incidental group but numbers did not reach statistical significance (17% vs 13%, P = 0.079). There were 270 cases in the ATA low-risk group (96%) and 12 cases in the ATA intermediate-risk group (4%). Patients with an ATA intermediate risk had a statistically higher number of capsule invasion, extrathyroidal extension and angioinvasion (P < 0.001, P < 0.001 and P < 0.001, respectively). Overall, 22% of patients with an incidental differentiated thyroid carcinoma should be considered for radioactive iodine 131I treatment. 29 of the 191 patients in American Joint Committee on Cancer stage I should be considered for radioactive iodine treatment (15%). Conclusions Males and patients with thyroiditis are at a higher risk for an incidental differentiated thyroid carcinoma. One of every five of patients diagnosed with cancer will need radioactive iodine treatment, even some patients with stage I disease.

Sign in / Sign up

Export Citation Format

Share Document